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Abstract
Few studies have evaluated weight change in patients who initiate medical marijuana treatment to address diagnosed health concerns. The objective of this study was to examine whether patients initiating medical marijuana use
for a qualifying health condition experienced changes in health and biopsychosocial functioning over time, including
weight gain or loss. Specifically, this observational, longitudinal study evaluated changes in the body mass index (BMI)
of adults with co-morbid obesity (body mass index [BMI] ≥ 30 kg/m2) and severe obesity (BMI ≥ 40 kg/m2) who were
starting medical marijuana treatment for any of the 23 qualifying medical conditions at one of three dispensaries in
Pennsylvania. Height and weight measurements were collected at baseline (prior to medical marijuana use) and then
90 days (± 14 days) later. Participants included in analyses (n = 52, M = 55.0 ± 13.6 years, 59.6% female) had a mean
baseline BMI of 36.2 ± 5.4 kg/m2 and the majority sought medical marijuana for chronic pain (73.1%). No significant
change in BMI was observed from baseline to month three (p > 0.05) in the sample. Additionally, no significant change
in BMI was observed in the subset of patients with severe obesity (n = 12, p > 0.05). Our findings are limited by low
follow-up rates and convenience sampling methodology but may help to mitigate weight gain concerns in the context of medical marijuana use.
Keywords: Obesity, Body weight, Medical marijuana, Clinical care
Access to medical marijuana continues to expand in the
USA (Han et al. 6), with 36 states and 4 territories currently allowing its use (National Conference of State Legislators 8). However, little is known about the relationship
between the use of medical marijuana and weight change
in patients with obesity initiating medical marijuana
therapy for qualifying conditions that frequently cooccur with obesity, such as chronic pain, anxiety disorders, and neuropathies (Okifuji and Hare 10; Scott et al.
14; Central obesity is associated with neuropathy in the
severely obese 3). On one hand, medical marijuana users
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may experience improvements in symptoms, resulting
in greater mobility and caloric expenditure (Sabia et al.
12), and in turn, potential reductions in body weight.
Conversely, and in accordance with the “munchies”
hypothesis (Beulaygue and French 2), marijuana use
may stimulate appetite in some patients (Gerich et al. 5;
Waissengrin et al. 15)or be associated with reductions in
initiative (aka, “amotivation”) (Sabia et al. 12), contributing to potential increases in body weight. Overall, the
relationship between Body Mass Index (BMI) and marijuana is not well-understood (Sabia et al. 12; Beulaygue
and French 2; Rodondi et al. 11; Sansone and Sansone
13). While some studies suggest lower BMI among users
relative to non-users (Beulaygue and French 2; Smit and
Crespo 15), higher caloric intake in users is also reported
(Smit and Crespo 15).
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As the rate of obesity remains high (Ogden et al. 9), and
the prevalence of medical marijuana therapy continues
to increase (Han et al. 6), it is important for providers to
better understand the relationship between medical marijuana use and weight change as it would help to inform
clinical obesity care (Diggins and Heinberg 4). To date,
several studies of weight-loss surgery patients suggest no
differences in weight outcomes between marijuana users
and non-users postoperatively (Shockcor et al. 2021;
Bauer et al. 1; Jung et al. 7); however, these studies did not
distinguish between recreational and medicinal products.
Given the oversight and regulations associated with medical marijuana dispensing (including patient qualifications, mode of delivery, dosing, and formulation), studies
of weight change in recreational marijuana users may not
be generalizable to medical marijuana users.
This paper used data from a larger ongoing observational study of the relationship between medical
marijuana treatment initiation and biopsychosocial
functioning over time. The primary objective of this
sub-study was to examine three-month post-initiation weight change in a sample of patients with obesity
(BMI ≥ 30.0 kg/m2) who began medical marijuana therapy for one of the 23 qualifying conditions in Pennsylvania (Supplementary Table 1). As a secondary objective,
weight change in the subset of patients with severe obesity (BMI ≥ 40.0 kg/m2) was also evaluated.

Method
The Institutional Review Board of the Philadelphia College of Osteopathic Medicine (#H17-060) provided oversight of this prospective, observational study. Participants
were recruited from three medical marijuana dispensaries located in the greater Harrisburg, Pennsylvania area
as a part of a larger longitudinal study of the impact of
medical marijuana therapy on quality of life. Eligible participants were at least 18 years of age, had a state-issued
medical marijuana card, and were naïve to medical marijuana therapy (a history of recreational use was allowed).
Potential participants were identified by the dispensary
pharmacists during new patient consultations. Interested
patients were then referred to onsite study staff. As part
of the informed consent process, potential participants
were informed that the study objective was to evaluate
how medical marijuana affects people’s health and functioning in different areas of their lives. After participants
provided informed consent, staff collected their demographic information along with their height (inches) and
weight (lbs.) (SECA 813, SECA Corp., Chino, CA) with
no shoes and light clothing. Participants returned in
90 days (± 14 days) to complete a follow-up assessment
that included weight measurement. Participants received
$25 for each study visit and a discount on their medical
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marijuana purchases. To be included in the analytic sample, individuals had to meet the established definition
of obesity (BMI ≥ 30.0 kg/m2) and have completed both
baseline and 3-month assessments. The datasets analyzed
are available in the DRYAD repository, https://datad
ryad.org/stash/share/vSsOklmIZBZOivCTILHPS7eAh
lVXgw_lTvO_z3ACm64.
We calculated descriptive statistics (e.g., means and
standard deviations, frequencies and percentages) on a
number of baseline demographic and status variables to
characterize the sample. We performed paired t-tests to
examine changes in BMI from baseline to the 3-month
follow-up for the overall sample of patients with obesity and for a subsample of patients who were identified
as living with severe obesity. To understand the impact
of attrition on the generalizability our findings, we conducted a series of independent t-tests to identify systematic differences among participants who did not attend
the 3-month follow-up. Cohen’s d was calculated as a
measure of effect size. Data were analyzed using SPSS
version 24.0 (IBM). It should be noted that data from the
baseline and month three assessment interviews were
used in the current analyses as it was our goal to examine
the early association between medical marijuana treatment initiation and body weight.

Results
At the time of this report, 290 patients were approached
for participation in the larger trial and 265 enrolled
(91.4%). Within this larger sample, 115 participants
were identified as having a BMI ≥ 30 kg/m2 at baseline,
with 33 (28.7%) meeting the criterion for severe obesity (BMI ≥ 40.0 kg/m2). The majority of these 115 participants were recommended medical marijuana to treat
chronic pain (65.2%) and/or anxiety (50.4%). A total of 52
participants (M = 55.0 ± 13.6 years, 59.6% female, 96.2%
White, 73.1% chronic pain) attended the 3-month followup assessment (45.2% follow-up rate) and were included
in analyses. All of these individuals reported that they
were still engaged in medical marijuana therapy. Participants who completed the three-month follow-up assessment were significantly older (t(113) = − 2.77, p = 0.007)
than those who did not complete three-month height
and weight assessments (M = 47.4 ± 15.4 years). The two
groups did not differ on any of the other of the baseline
variables examined (all ps > 0.05).
At the time of study entry, participants reported the
most common purchases at the dispensaries to be tinctures (61.5%), topicals (38.5%), capsules (40.4%), disposable pens (17.3%), and cartridges (76.8%) (multiple
product purchases possible). All products contained
THC or a combination of THC and CBD. At 3 months, all
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participants included in analyses endorsed continued use
of medical marijuana.
No significant differences in BMI were found
from baseline (M = 36.2 ± 5.4 kg/m2) to 3 months
(M = 36.6 ± 5.9 kg/m2) for the 52 participants with obesity that completed both assessments to the 3-month
follow-up assessment, t[51] = − 0.89, p > 0.05, d = −
0.07. Similar null results were observed for the subset of
patients with severe obesity (n = 12). BMI values were not
significantly different at baseline (M = 44.4 ± 4.0 kg/m2)
and 3-month follow-up (M = 44.0 ± 4.8 kg/m2) for this
subgroup of participants, t(11) = 1.22, p > 0.05, d = 0.10.

Discussion
The current study found that patients with obesity initiating medical marijuana treatment for any of the
qualifying conditions in Pennsylvania, most commonly
chronic pain and anxiety, did not experience significant
weight changes over the first 3 months of medical marijuana use. These findings provide preliminary evidence
to help alleviate concerns from patients with obesity, or
their recommending physicians, that medical marijuana
may adversely impact weight. Further, behavioral weight
management patients presenting with conditions that
frequently co-occur with obesity, such as chronic pain
(Okifuji and Hare 10), may be able to continue medical
marijuana during weight-loss treatment without concerns for medical marijuana-related weight gain. Given
our similarly null findings in the small subset of patients
with severe obesity as well, weight loss surgery providers
could consider restarting medical marijuana in postoperative patients when medically indicated. However, our
findings are notably limited by our small samples and
underpowered analyses and therefore represent an initial
step in our understanding of weight change in the context of medical marijuana therapy.
Our study findings are also limited by the observational design, predominantly White sample, convenience sampling, and the low follow-up rate at 3 months
(45.2%) due to face-to-face restrictions placed on dispensaries at times during the pandemic. Specifically,
patients were not permitted inside the dispensaries
for the majority of the duration of this study due to
COVID-19, and therefore, follow-up weights were not
obtained from patients who did not feel comfortable
attending outdoor, curbside study visits due to COVID19 concerns. Additionally, participants may have been
weighed at different times of the day at baseline and
3 months, which could impact weight outcomes. Additionally, it is possible that informing participants of
the study’s objective (i.e., to examine changes in various health outcomes over time) could have created a
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demand characteristic resulting in participants being
more mindful of their caloric intake or expenditure
during the study duration. Studies with more rigorous
experimental designs that incorporate larger and more
diverse samples, measures of dietary intake and physical activity, and longer follow-up intervals are needed
to further clarify the relationship between medical
marijuana therapy and weight change in patients with
obesity. As the body of marijuana-focused research
continues to expand, differentiating between studies
of recreational and medicinal users could be of benefit
given that medicinal users may have different reasons
for, and expectations of, marijuana use. Furthermore,
medicinal users are using marijuana products with
known profiles and are under the care of providers.
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